Skip to main content
Journal cover image

Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

Publication ,  Journal Article
Held, C; White, HD; Stewart, RAH; Davies, R; Sampson, S; Chiswell, K; Silverstein, A; Lopes, RD; Heldestad, U; Budaj, A; Mahaffey, KW ...
Published in: Am Heart J
February 2019

BACKGROUND: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with stable coronary heart disease. METHODS: Investigators were instructed to report all potential events. Each reported event was reviewed independently by 2 reviewers according to prespecified processes and prespecified end point definitions. Concordance between reported and adjudicated cardiovascular (CV) events was evaluated, as well as event classification influence on final study results. RESULTS: In total, CEC reviewed 7,096 events: 1,064 deaths (696 CV deaths), 958 myocardial infarctions (MI), 433 strokes, 182 transient ischemic attacks, 2,052 coronary revascularizations, 1,407 hospitalizations for unstable angina, and 967 hospitalizations for heart failure. In total, 71.8% events were confirmed by CEC. Concordance was high (>80%) for cause of death and nonfatal MI and lower for hospitalization for unstable angina (25%) and heart failure (50%). For the primary outcome (composite of CV death, MI, and stroke), investigators reported 2,086 events with 82.5% confirmed by CEC. The STABILITY trial treatment effect of darapladib versus placebo on the primary outcome was consistent using investigator-reported events (hazard ratio 0.96 [95% CI 0.87-1.06]) or adjudicated events (hazard ratio 0.94 [95% CI 0.85-1.03]). CONCLUSIONS: The primary outcome results of the STABILITY trial were consistent whether using investigator-reported or CEC-adjudicated events. The proportion of investigator-reported events confirmed by CEC varied by type of event. These results should help improve event identification in clinical trials to optimize ascertainment and adjudication.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2019

Volume

208

Start / End Page

65 / 73

Location

United States

Related Subject Headings

  • Stroke
  • Placebos
  • Phospholipase A2 Inhibitors
  • Percutaneous Coronary Intervention
  • Oximes
  • Myocardial Infarction
  • Kaplan-Meier Estimate
  • Ischemic Attack, Transient
  • Humans
  • Hospitalization
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Held, C., White, H. D., Stewart, R. A. H., Davies, R., Sampson, S., Chiswell, K., … STABILITY Investigators. (2019). Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J, 208, 65–73. https://doi.org/10.1016/j.ahj.2018.10.010
Held, Claes, Harvey D. White, Ralph A. H. Stewart, Richard Davies, Shani Sampson, Karen Chiswell, Adam Silverstein, et al. “Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.Am Heart J 208 (February 2019): 65–73. https://doi.org/10.1016/j.ahj.2018.10.010.
Held C, White HD, Stewart RAH, Davies R, Sampson S, Chiswell K, Silverstein A, Lopes RD, Heldestad U, Budaj A, Mahaffey KW, Wallentin L, STABILITY Investigators. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J. 2019 Feb;208:65–73.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

February 2019

Volume

208

Start / End Page

65 / 73

Location

United States

Related Subject Headings

  • Stroke
  • Placebos
  • Phospholipase A2 Inhibitors
  • Percutaneous Coronary Intervention
  • Oximes
  • Myocardial Infarction
  • Kaplan-Meier Estimate
  • Ischemic Attack, Transient
  • Humans
  • Hospitalization